Flogan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flogan

Flogan is a pharmaceutical product primarily used for providing localized relief from pain and inflammation. Its active component is Diclofenac, which belongs to the class of medicines known as Non-steroidal anti-inflammatory drugs (NSAIDs). This preparation is a single-ingredient, synthetic compound derived from phenylacetic acid. Flogan is recognized for its unique topical gel formulation designed for efficient skin delivery.

Property Description
Active ingredient Diclofenac diethylamine
Form Topical gel (Emulgel)
Pharmacological class Non-steroidal anti-inflammatory drug (NSAID)
Common use Localized pain and inflammation relief
Origin Synthetic compound

What Type of Medicine Is Flogan?

Flogan is formally classified as a Non-steroidal anti-inflammatory drug (NSAID), a pharmacological category that signifies its core purpose is to counteract inflammation and reduce pain. The active ingredient, Diclofenac, achieves this by modulating the creation of natural chemical messengers—primarily prostaglandins—that initiate the body's inflammatory response. Diclofenac preparations are classified among the essential medicines for musculoskeletal disorders. This classification confirms that Flogan's mechanism focuses on treating the source of tissue irritation. Flogan is specifically formulated for cutaneous administration, distinguishing its use from oral NSAID forms; this local route is clinically recognized for maximizing concentration at the point of application.

Composition and Form: Flogan Topical Gel

The product is a single-ingredient preparation delivered as a specialized form called a topical gel, also often referred to as an Emulgel. The specific active component is the salt form, Diclofenac diethylamine. A key differentiating factor is the unique Emulgel base, which is engineered to enhance the penetration of the active substance through the skin's outer layers, effectively delivering the Diclofenac into the underlying tissues. Topical Diclofenac formulations are used for localized application with minimal systemic exposure. The gel's formulation is designed to deliver its effects primarily to the local area, such as in cases of joint or muscle strain.

General Purpose: Localized Relief

The overall general purpose of Flogan is to offer localized analgesic (pain-relieving) and anti-inflammatory benefits. By delivering the NSAID directly to the affected area via the skin, the preparation works to reduce the swelling, heat, and discomfort associated with localized irritations, supporting the body's natural processes of symptom alleviation. Flogan is typically used for common issues like temporary muscle aches or tenderness near joints.

Regulatory References

  1. NIH StatPearls: Diclofenac

What side effects are possible with Flogan?

Possible Side Effects and Safety Information

Flogan, which contains Diclofenac, a Non-steroidal anti-inflammatory drug (NSAID), has a safety profile characterized primarily by effects at the site of application. The possibility of systemic adverse reactions, which are commonly associated with the NSAID class, cannot be excluded, particularly with use over large skin areas or for prolonged periods.


Adverse Reaction Classification

Official regulatory documents classify adverse reactions based on their frequency. The most common effects involve the Skin and subcutaneous tissue disorders:

Frequency Category Representative Adverse Reactions
Common (1 in 10 to 1 in 100 people) Dermatitis (including contact dermatitis), Rash, Pruritus (itching), Eczema, Erythema
Rare (1 in 1,000 to 1 in 10,000 people) Dermatitis bullous (blistering skin inflammation)
Very Rare (Less than 1 in 10,000 people) Hypersensitivity, Angioedema, Asthma, Photosensitivity reaction

High-Level Safety Considerations

Due to its classification as an NSAID, the product label documents potential serious systemic risks. These are generally rare for topical application but include warnings regarding serious Gastrointestinal Events (e.g., bleeding, ulceration), Cardiovascular Thrombotic Events (e.g., Myocardial Infarction, Stroke), and Severe Cutaneous Adverse Reactions.

Population and Exposure Constraints

Safety statements stipulate that use is contraindicated during the third trimester of pregnancy due to the potential for fetal harm. Additionally, the treated area should not be exposed to natural or artificial sunlight because of the risk of photosensitivity. Older adults are noted as being at greater risk for developing serious systemic adverse events if significant absorption occurs.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory overdose profile for Flogan (Diclofenac topical gel) is primarily defined by the risk of accidental oral ingestion, as systemic absorption through the skin is generally low. Overdose manifestations following ingestion are consistent with systemic Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Documented Overdose Manifestations Systemic overdose may present with signs such as gastrointestinal irritation, vomiting, nausea, headache, dizziness, or disorientation. Severe, life-threatening outcomes can include gastrointestinal bleeding, acute renal failure, and serious cardiovascular events like stroke or myocardial infarction. The official documentation confirms that no specific antidote is known for Diclofenac poisoning, and management involves supportive and symptomatic treatment for complications.

Required Emergency Action Government labeling explicitly mandates that if Flogan is swallowed, immediate medical help must be sought, or a Poison Control Center must be contacted right away. Urgent medical assistance is also required if signs of a severe allergic reaction (e.g., hives, facial swelling, or wheezing) manifest, irrespective of the route of exposure.

Population-Specific Considerations Regulatory information notes an increased risk of severe gastrointestinal bleeding in patients aged 60 or older. The systemic effects of Diclofenac are contraindicated in late pregnancy (20 weeks or later) due to documented risks to the developing fetus.

Therapeutic Uses of Flogan

What Flogan Treats: Main Uses and Benefits

Flogan, a diclofenac topical preparation, is applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort and symptoms related to inflammatory or irritative states. It is generally applicable for easing symptoms in the musculoskeletal system for adults and adolescents aged 14 years and over.

The preparation is relevant for managing symptoms that interfere with daily comfort across conditions involving episodic or fluctuating manifestations, such as strains, sprains, contusions, localized pain associated with osteoarthritis, and soft tissue rheumatism like tendonitis.

“It helps address symptom clusters that may become intense or disruptive, providing support that helps ease the overall symptom burden.”

Flogan is applied in addressing both symptoms related to physical discomfort and symptoms related to inflammatory or irritative states (such as swelling and heat). This symptomatic assistance is needed when symptoms create noticeable physiological strain. By providing this targeted support, the medication may assist with maintaining functional stability, and contributes to improved comfort during symptomatic periods.


Quick Fact: Relief for Symptoms Related to Physical Discomfort and Inflammatory States

Eligibility and Restrictions for Use

Official Population Eligibility for Flogan

Flogan (Diclofenac Topical Gel) eligibility is strictly defined by regulatory authorities and depends on age, specific medical history, and physiological status.

Contraindicated Populations
Patients with known hypersensitivity or allergic reactions (including asthma or hives) to diclofenac, aspirin, or any other NSAIDs
Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery (peri-operative pain)
Pregnant women starting at 30 weeks gestation (Third Trimester)
Age-Related Eligibility
Adults and Adolescents aged 14 years and over are generally considered eligible populations (minimum age may vary by region)
Use in patients under 14 years is generally not recommended or not established for safety and efficacy
Older adults are generally permitted to use the medicine but require caution and monitoring
Conditional Restrictions
Use must be avoided in cases of advanced renal disease or severe heart failure
The gel must not be applied to damaged, non-intact, or infected skin, including open wounds
Use during pregnancy from 20 to 30 weeks is generally avoided unless clearly necessary
Use during lactation (breastfeeding) is generally considered acceptable due to low systemic absorption, provided the infant does not contact the treated area

This information reflects the official eligibility status, restrictions, and contraindications listed in government-approved prescribing information.

What should I know about interactions with other medicines?

Flogan Interactions with other medicines and products

The interaction profile for Flogan, a topical Non-steroidal Anti-inflammatory Drug (NSAID), is structured by potential systemic risks associated with the active ingredient Diclofenac and administration-specific constraints, as documented in government regulatory sources.

Drug-Drug and Pharmacodynamic Interactions

Co-administration with other Oral NSAIDs or Aspirin (at analgesic doses) is generally not recommended by regulatory bodies because it substantially increases the risk of serious gastrointestinal events without providing increased clinical benefit.

Interacting Substance/Class Officially Documented Interaction Outcome
Anticoagulants (e.g., Warfarin) Increased risk of serious GI bleeding due to additive effects on hemostasis.
Anti-Hypertensive Agents (e.g., ACE Inhibitors, ARBs) May diminish the therapeutic antihypertensive effect of the medication.
Diuretics Can reduce the natriuretic and diuretic efficacy, potentially resulting in fluid retention.
Digoxin and Lithium May increase the serum concentration and prolong the half-life of these medications.

Topical and Population-Based Restrictions

A regulatory restriction is applied to the application site: concurrent use with any other topical product must be avoided on the same skin site. Furthermore, the interaction with ACE Inhibitors and ARBs leading to potential deterioration of renal function is noted as more significant in elderly, volume-depleted, or renal-impaired patients.

Mechanism of Action

Inhibition of the COX Enzyme System

The primary mechanism of Flogan involves the active ingredient, Diclofenac, acting as a reversible inhibitor of the Cyclooxygenase ( COX) enzymes, particularly the COX-2 isoform. This mechanism engages the biological systems where prostaglandins dominate the physiological response, thereby suppressing an early molecular step in the cascade that leads to the generation of localized inflammatory signals.


Modulation of the Arachidonic Acid Pathway

By blocking COX activity, the drug directly modulates the Arachidonic Acid Pathway, significantly reducing the synthesis of inflammatory prostaglandin mediators. This suppression of mediator supply results in reduced vasodilation and lessened capillary permeability, leading to predictable physiological adjustments and attenuation of heightened local tissue responses.


Dampening Peripheral Nociceptive Signals

A key physiological consequence of the reduced prostaglandin level is the dampening of peripheral nociceptive signaling. Prostaglandins typically increase local nerve excitability; their reduction limits this sensitization, modulating activity within the nociceptive signaling pathways.

Dosage and Administration Information

How Flogan is Used

Flogan (Diclofenac topical gel) is administered exclusively via the cutaneous route for localized application. This approach is independent of meal timing.


Official Dosing and Frequency

The standard dosage for this preparation is measured by the length or mass of the gel applied to the affected area. For instance, the regimen for the 1% concentration may involve applying 2 g or 4 g of gel per dose, with the total daily dose strictly not exceeding specified limits, such as 32 g per day across all affected joints. The frequency of application depends on the strength of the formulation, typically ranging from twice daily for the 2.32% concentration up to four times daily for the 1% concentration.


Administration Procedure and Duration

The gel must be measured accurately, often using a dosing card or strip, and then gently massaged into the skin over the entire affected area until it is fully absorbed. After application, the hands should be washed immediately, unless they are the site of treatment. Standard instructions for application set constraints, requiring the product to be applied only to intact, non-diseased skin and prohibiting the use of occlusive dressings or external heat.

For acute conditions like muscle and joint injuries, the treatment duration should generally not exceed seven days without a re-evaluation. If a dose is missed, the patient is instructed to skip the dose and resume the usual schedule, without applying a double amount to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flogan

The research base for Flogan, which is a topical gel containing diclofenac, consists of controlled clinical trials and large-scale systematic reviews. This evidence focuses on research examining outcomes related to chronic joint conditions and outcomes related to acute injuries. The evidence highlights what is known and what is still uncertain; findings describe group patterns, not personal outcomes.


Evidence for Chronic Localized Pain (Osteoarthritis)

Research has primarily examined topical diclofenac gel in adults and older adults who participated in studies of localized, chronic conditions such as osteoarthritis (OA) of the knee and hand. These studies were most often short-term, randomized controlled trials (RCTs) that compared the topical gel against a non-medicated vehicle (a placebo gel). Outcomes related to physical discomfort were monitored, alongside measurements reflecting daily functioning or activity level.

Studies exploring how symptoms change over time reported that the measurements of pain intensity described by participants using the active gel differed compared to those reported by participants using the non-medicated vehicle over follow-up periods of up to 12 weeks. Findings describe patterns observed in the studies related to outcomes linked to physical discomfort. Research examined studies that used oral anti-inflammatory medicines as a study comparator.


Evidence for Acute Soft Tissue Injuries

Topical diclofenac was also evaluated in studies examining patient-reported experiences relevant in trials assessing short-term or episodic symptom patterns, such as recent sprains, strains, or contusions. Research explored short-term symptom changes in adults and adolescents aged 14 and over. These trials assessed outcomes describing episodic or acute changes and measured how symptoms evolved in the observed populations over defined time intervals, typically lasting only a few days to two weeks.

In studies conducted during periods of increased symptom activity, the research described that measurements of rapid changes in pain intensity and observed tenderness differed when comparing the topical diclofenac gel to a non-medicated control gel.


Research Gaps and Areas of Uncertainty

Evidence is limited in several key areas. Research has primarily focused on easily accessible joints, and data for certain groups remain insufficient, such as for the use of the topical gel on deep joints like the hip or spine. Additionally, while data show patterns related to short-term changes, long-term effects on functional outcomes are not fully established through extended controlled trials. Findings were mixed in some areas, and data for children under 14 years of age remain insufficient. Subgroup findings are uncertain, and results apply only to the populations studied in the official research.

Frequently Asked Questions (FAQ)

Common questions about Flogan (FAQ)


Q: What is the typical time frame to notice Flogan starting to work?

Studies and official information indicate that the time to first relief can vary between individuals and the condition being addressed. Clinical studies often report differences in symptom measurements when comparing the active gel to a non-medicated gel over observation periods of several days to a few weeks.


Q: How long does the effect of one dose of Flogan generally last?

Regulatory documents indicate the typical frequency of application. The frequency described in product labeling is typically two to four times a day, which reflects the period over which the effects of the dose are generally managed in the body.


Q: Is Flogan safe to take if I sometimes consume alcohol?

Official drug information states that avoiding or limiting the consumption of alcohol is noted while using the active ingredient in Flogan, Diclofenac. This caution is stated because the combination may potentially increase the risk of stomach irritation and gastrointestinal bleeding.


Q: What are the most common side effects people report after starting Flogan?

The most common side effects reported for Flogan involve reactions at the site of application on the skin. These frequently observed effects include mild skin irritation, redness, rash, or itching (pruritus). Serious systemic reactions are considered rare with topical use.


Q: Is it true that Flogan can affect the stomach or cause digestive issues?

Yes, regulatory documents note that Flogan, as an NSAID, carries a systemic risk for serious gastrointestinal (stomach and intestine) adverse events like bleeding or ulceration. The potential risk is noted, particularly when the gel is used over large skin areas or for prolonged periods.


Q: Can Flogan affect the results of certain medical lab tests?

Official drug information notes that Diclofenac can interact with certain other medications that are monitored through blood tests, such as Digoxin and Lithium. The interaction may affect the measured concentration of those substances, which is a factor to consider in laboratory monitoring.


Q: Does Flogan interact with common medicines used to treat anxiety or depression?

Regulatory documents state a potential interaction between NSAIDs like Flogan and certain antidepressant medications, specifically those categorized as SSRIs or SNRIs. This combination may increase the overall risk of bleeding complications.


Q: Is Flogan appropriate for use in children or teenagers?

Official authorized use is generally established for adults and adolescents aged 14 years and older. The use of Flogan in patients under 14 years is outside the established age range defined in product information.


Q: Are there any specific activities, like driving, that Flogan might interfere with?

Although generally rare with topical administration due to low systemic absorption, official product information for Diclofenac mentions potential systemic side effects like dizziness or drowsiness. These effects are noted in the official product information and may be a factor when performing activities that require full attention, such as driving or operating machinery.


Q: Is it possible to develop a dependency on Flogan with long-term use?

Flogan is classified as a Non-steroidal Anti-inflammatory Drug (NSAID) and is not designated as a controlled substance. Regulatory classification indicates that, as an NSAID, Flogan is not associated with the risk of physical dependency seen with controlled substances like opioids.


Q: Do generic versions of Flogan work exactly the same as the brand name?

Regulatory bodies require that generic versions of any approved medicine must demonstrate bioequivalence to the original brand-name product. This means that generic formulations are required to demonstrate that they are comparable to the original in terms of therapeutic benefit.


Q: Can Flogan be taken on an empty stomach?

As Flogan is a topical gel applied to the skin, its administration is not dependent on food or meal timing. This is a point of difference compared to oral forms of NSAIDs.


Q: Can Flogan make you feel tired or drowsy?

Drowsiness (somnolence) and dizziness are listed as possible systemic side effects reported for the active ingredient, Diclofenac, in the regulatory information.


Q: Are there certain foods or drinks that should be avoided while taking Flogan?

Official information generally does not list specific foods that must be avoided while using Flogan. However, the use of alcohol is often noted as a potential exception, as consuming it may increase the risk of systemic side effects like stomach bleeding.


Q: What is the evidence regarding Flogan's effectiveness in managing chronic pain?

Clinical studies have examined the use of Flogan in localized, chronic conditions such as osteoarthritis of the knee and hand. These studies described that measurements of pain and function reported by participants using the active gel differed compared to those using a non-medicated gel over observation periods of up to 12 weeks.


Q: What does the research say about the long-term safety profile of Flogan?

Due to low systemic absorption, the risk of serious systemic side effects is noted to be reduced with topical use. However, official warnings state that systemic risks cannot be completely excluded, especially if the product is used over large areas of the body or for prolonged periods of time.


Q: Has Flogan been linked to any issues with fertility?

Official documents note that NSAIDs, the class of drugs Flogan belongs to, may be associated with a potential for reversible impairment of female fertility. This is a general class effect that is noted in the product information.


Q: Why is Flogan contraindicated for people who have had certain surgical procedures?

Flogan is contraindicated in the setting of peri-operative pain from Coronary Artery Bypass Graft (CABG) surgery. The restriction is based on the official determination that NSAIDs, as a drug class, are associated with an increased risk of serious cardiovascular thrombotic events in the setting of this surgery.


Q: What information is available about the risk of bleeding with Flogan?

As an NSAID, Flogan is officially associated with a warning for the risk of serious gastrointestinal bleeding. Regulatory information indicates that the risk of gastrointestinal bleeding is noted as higher for certain populations, such as older adults or those using specific concurrent medications.

How should Flogan be stored and disposed of?

Storage and Disposal Requirements for Flogan (Diclofenac Topical Gel)

Flogan must be stored strictly according to official regulatory guidelines to maintain its stability and effectiveness.

Storage Conditions

The gel must be stored at controlled room temperature, generally between 20°C to 25°C. It is required that the product not be frozen and be kept away from excessive heat or open flame. Store Flogan in its original, tightly closed container and keep it out of the sight and reach of children.

Disposal

Unused or expired Flogan must not be thrown away in the household trash or disposed of via wastewater. This is due to the potential risk of the active ingredient to the aquatic environment. Dispose of the unused medicine and any waste material in accordance with local requirements, often by returning it to a pharmacy or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flogan found in:

A-Z Index: